New anxiety drug candidate SYT-510 enters early human testing
NCT ID NCT07478744
First seen Mar 25, 2026 · Last updated Jun 16, 2026 · Updated 17 times
Summary
This early study will test a single dose of an experimental drug called SYT-510 in 24 adults with generalized anxiety disorder. The goal is to see if the drug can reduce anxiety-related brain activity and defensive behaviors, and to check its safety. Participants will receive both the drug and a placebo at different times to compare effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.